| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Sep'17 | Jun'17 |
|---|---|---|---|---|---|---|---|---|---|---|
Net revenue | ||||||||||
498,533 | 397,328 | 378,283 | 404,642 | 446,120 | 497,528 | 476,487 | 413,787 | 275,189 | 254,733 | 259,871 |
Cost of goods sold | ||||||||||
313,578 | 273,373 | 267,717 | 296,381 | 309,743 | 304,120 | 268,567 | 235,492 | 130,594 | 119,720 | 136,138 |
Cost of goods sold impairment charges | ||||||||||
1,456 | 13,721 | 56,132 | 3,012 | 53,297 | 0 | 7,815 | 0 | 0 | - | - |
Gross profit | ||||||||||
183,499 | 110,234 | 54,434 | 105,249 | 83,080 | 193,408 | 200,105 | 178,295 | 144,595 | 135,013 | 123,733 |
Selling, general and administrative | ||||||||||
77,976 | 74,084 | 63,797 | 67,281 | 84,436 | 71,236 | 75,486 | 56,003 | 25,121 | 27,440 | 26,938 |
Research and development | ||||||||||
36,379 | 48,050 | 38,125 | 48,016 | 53,858 | 57,297 | 42,349 | 50,335 | 44,209 | 41,323 | 47,184 |
In-process research and development impairment charges | ||||||||||
960 | 450 | 23,382 | 0 | 22,787 | 38,609 | 650 | 0 | 0 | - | - |
Intellectual property legal development expenses | ||||||||||
1,270 | 4,975 | 2,586 | 2,511 | 4,166 | 3,237 | 4,401 | 4,047 | 4,576 | 6,693 | 4,926 |
Acquisition, transaction-related and integration expenses | ||||||||||
2,575 | 3,706 | 3,131 | 3,519 | 6,032 | 4,945 | 2,231 | 207,507 | 7,135 | 2,271 | 82 |
Charges related to legal matters | ||||||||||
-4,500 | 2,308 | -14,750 | 0 | 0 | - | -2,589 | 3,000 | - | 21,467 | - |
Restructuring and other charges | ||||||||||
2,048 | 4,412 | 20,937 | 2,835 | 6,161 | 14,104 | -2,156 | 44,465 | 0 | 0 | 0 |
Operating income (loss) | ||||||||||
57,791 | -23,135 | -112,274 | -18,913 | -94,360 | 23,280 | 74,555 | -181,062 | 63,554 | 78,753 | 44,603 |
Other (expense) income: | ||||||||||
Interest expense, net | ||||||||||
-39,899 | -38,829 | -42,209 | -43,886 | -43,281 | -42,880 | -43,018 | -36,622 | -21,051 | -19,218 | -17,726 |
Foreign exchange loss, net | ||||||||||
-5,181 | 4,722 | -12,531 | 8,311 | -5,464 | 2,817 | -5,137 | -25,946 | 8,565 | -4,178 | 15,332 |
Loss on extinguishment of debt | ||||||||||
- | - | 0 | 0 | - | - | 0 | -19,667 | - | 0 | -2,531 |
Gain on sale of international business | ||||||||||
0 | 328 | 0 | -1,888 | 8,818 | -146 | -2,812 | 0 | 0 | -28,880 | - |
Gain from reduction of tax receivable agreement liability | ||||||||||
- | - | 192,844 | - | - | - | 0 | - | - | - | - |
Other income, net | ||||||||||
633 | -237 | 446 | 149 | 1,107 | 458 | -1,014 | 791 | 948 | -93 | -78 |
Total other expense, net | ||||||||||
-44,447 | -33,976 | 138,550 | -37,314 | -38,820 | -38,086 | -51,981 | -81,444 | -11,538 | -52,369 | -5,003 |
Income (loss) before income taxes | ||||||||||
13,344 | -57,111 | 26,276 | -56,227 | -133,180 | -14,806 | 22,574 | -262,506 | 52,016 | 26,384 | 39,600 |
Benefit from income taxes | ||||||||||
-108,000 | 7,364 | 389,668 | -5,701 | -8,000 | 5,488 | 5,109 | -12,416 | 400 | -738 | 1,852 |
Net income (loss) | ||||||||||
121,517 | -64,903 | -363,392 | -50,526 | -124,752 | -20,330 | 17,465 | -250,090 | 51,652 | 27,122 | 37,748 |
Less: Net loss (income) attributable to Amneal Pharmaceuticals LLC pre-Combination | ||||||||||
- | - | 0 | 0 | - | 0 | 0 | -200,341 | 51,535 | 26,780 | 37,446 |
Less: Net (income) loss attributable to non-controlling interests | ||||||||||
6,450 | -32,775 | -98,386 | -33,624 | -76,871 | -11,562 | 10,577 | -31,885 | 117 | 342 | 302 |
Net income (loss) attributable to Amneal Pharmaceuticals, Inc. | ||||||||||
115,067 | -32,128 | -265,006 | -16,902 | -47,881 | - | 6,888 | -17,864 | - | 0 | 0 |
Accretion of redeemable non-controlling interest | ||||||||||
- | - | 0 | 0 | - | - | -64 | 1,240 | - | 0 | 0 |
Net loss attributable to Amneal Pharmaceuticals, Inc. | ||||||||||
- | - | -265,006 | -16,902 | - | -8,768 | 6,952 | -19,104 | 0 | 0 | 0 |
Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.'s common stockholders: | ||||||||||
Class A and Class B-1 basic | ||||||||||
0.78 | - | -2.03 | - | -0.37 | - | 0.05 | - | - | - | - |
Class A and Class B-1 diluted | ||||||||||
0.78 | - | -2.03 | - | -0.37 | - | 0.05 | - | - | - | - |
Class A and Class B-1 basic and diluted | ||||||||||
- | - | - | -0.13 | - | - | - | -0.15 | - | - | - |
Weighted-average common shares outstanding: | ||||||||||
Class A and Class B-1 basic | ||||||||||
147,180 | - | 130,729 | - | 127,687 | - | 127,247 | - | - | - | - |
Class A and Class B-1 diluted | ||||||||||
147,956 | - | 130,729 | - | 127,687 | - | 128,222 | - | - | - | - |
Class A and Class B-1 basic and diluted | ||||||||||
- | - | - | 128,016 | - | - | - | 127,112 | - | - | 0 |